50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
How To Earn a Tax-Advantaged 10% Dividend Yield (Ad)pixel
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
One Stock Doubles Your Money, During Crisis? (Ad)
MarketBeat: Week in Review 9/19 – 9/23
China using civilian ships to enhance navy capability, reach
One Stock Doubles Your Money, During Crisis? (Ad)
German leader seeks energy deals, alliances on Gulf trip
World Bank head says he's not a climate denier, won't quit
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
How To Earn a Tax-Advantaged 10% Dividend Yield (Ad)pixel
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
One Stock Doubles Your Money, During Crisis? (Ad)
MarketBeat: Week in Review 9/19 – 9/23
China using civilian ships to enhance navy capability, reach
One Stock Doubles Your Money, During Crisis? (Ad)
German leader seeks energy deals, alliances on Gulf trip
World Bank head says he's not a climate denier, won't quit
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
How To Earn a Tax-Advantaged 10% Dividend Yield (Ad)pixel
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
One Stock Doubles Your Money, During Crisis? (Ad)
MarketBeat: Week in Review 9/19 – 9/23
China using civilian ships to enhance navy capability, reach
One Stock Doubles Your Money, During Crisis? (Ad)
German leader seeks energy deals, alliances on Gulf trip
World Bank head says he's not a climate denier, won't quit
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
How To Earn a Tax-Advantaged 10% Dividend Yield (Ad)pixel
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
One Stock Doubles Your Money, During Crisis? (Ad)
MarketBeat: Week in Review 9/19 – 9/23
China using civilian ships to enhance navy capability, reach
One Stock Doubles Your Money, During Crisis? (Ad)
German leader seeks energy deals, alliances on Gulf trip
World Bank head says he's not a climate denier, won't quit
NASDAQ:SPRO

Spero Therapeutics - SPRO Stock Forecast, Price & News

$1.97
-0.23 (-10.45%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.92
$2.41
50-Day Range
$0.68
$2.20
52-Week Range
$0.68
$19.87
Volume
41.73 million shs
Average Volume
18.90 million shs
Market Capitalization
$69.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.67

Spero Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
238.4% Upside
$6.67 Price Target
Short Interest
Healthy
1.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.80
Upright™ Environmental Score
News Sentiment
0.66mentions of Spero Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$5,355 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.42) to ($1.34) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.71 out of 5 stars

Medical Sector

91st out of 1,080 stocks

Pharmaceutical Preparations Industry

26th out of 535 stocks

SPRO stock logo

About Spero Therapeutics (NASDAQ:SPRO) Stock

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Receive SPRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SPRO Stock News Headlines

Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK
What’s the Obsession Over Inflation?
Before you waste your time arguing about inflation, how about we focus on the facts? 61% of American families are scrambling to make ends meet. Now is your time to grow your capital. With this TOOL, you can. Learn to predict market trends 1 - 3 days in advance with up to 87.4% proven accuracy. Save Your Seat in a Free Live Training Here. pixel
What’s the Obsession Over Inflation?
Before you waste your time arguing about inflation, how about we focus on the facts? 61% of American families are scrambling to make ends meet. Now is your time to grow your capital. With this TOOL, you can. Learn to predict market trends 1 - 3 days in advance with up to 87.4% proven accuracy. Save Your Seat in a Free Live Training Here. pixel
Spero Therapeutics Rises
Spero (SPRO) Up Following Positive FDA Update for UTI Drug
See More Headlines
Receive SPRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SPRO Company Calendar

Last Earnings
11/10/2021
Today
9/24/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SPRO
Fax
N/A
Employees
146
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.67
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+238.4%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-89,760,000.00
Net Margins
-1,147.64%
Pretax Margin
-1,147.64%

Debt

Sales & Book Value

Annual Sales
$18.26 million
Book Value
$2.73 per share

Miscellaneous

Free Float
33,538,000
Market Cap
$69.09 million
Optionable
Optionable
Beta
1.87

Key Executives

  • Dr. Ankit Mahadevia M.D.Dr. Ankit Mahadevia M.D. (Age 41)
    MBA, Co-Founder, Pres, CEO & Director
    Comp: $924.28k
  • Mr. Satyavrat Shukla C.F.A. (Age 50)
    CFO & Treasurer
    Comp: $788.84k
  • Ted Jenkins
    VP & Head of Investor Relations
  • Ms. Tamara Lynn Joseph L.L.M. (Age 59)
    Chief Legal Officer
  • Mr. James P. Brady
    Chief Human Resource Officer
  • Mr. Timothy Keutzer (Age 54)
    Chief Devel. Officer
  • Dr. Ian A. Critchley
    Head of Clinical Microbiology
  • Dr. Susannah Walpole Ph.D.
    Head of Clinical Operations
  • Dr. Angela Talley
    Sr. VP of Clinical Devel.













SPRO Stock - Frequently Asked Questions

Should I buy or sell Spero Therapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SPRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SPRO, but not buy additional shares or sell existing shares.
View SPRO analyst ratings
or view top-rated stocks.

What is Spero Therapeutics' stock price forecast for 2022?

5 analysts have issued 12 month price targets for Spero Therapeutics' shares. Their SPRO share price forecasts range from $5.00 to $8.00. On average, they expect the company's stock price to reach $6.67 in the next twelve months. This suggests a possible upside of 238.4% from the stock's current price.
View analysts price targets for SPRO
or view top-rated stocks among Wall Street analysts.

How have SPRO shares performed in 2022?

Spero Therapeutics' stock was trading at $16.01 at the beginning of 2022. Since then, SPRO stock has decreased by 87.7% and is now trading at $1.97.
View the best growth stocks for 2022 here
.

When is Spero Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our SPRO earnings forecast
.

How were Spero Therapeutics' earnings last quarter?

Spero Therapeutics, Inc. (NASDAQ:SPRO) released its earnings results on Wednesday, November, 10th. The company reported ($0.70) EPS for the quarter, missing analysts' consensus estimates of ($0.66) by $0.04. The firm earned $3.06 million during the quarter, compared to analyst estimates of $3 million. Spero Therapeutics had a negative net margin of 1,147.64% and a negative trailing twelve-month return on equity of 151.75%. During the same period in the previous year, the firm earned ($0.86) EPS.

What is Ankit Mahadevia, MD's approval rating as Spero Therapeutics' CEO?

27 employees have rated Spero Therapeutics Chief Executive Officer Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among the company's employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Spero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), Kadmon (KDMN), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN).

When did Spero Therapeutics IPO?

(SPRO) raised $75 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

What is Spero Therapeutics' stock symbol?

Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."

Who are Spero Therapeutics' major shareholders?

Spero Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.86%), Millennium Management LLC (0.96%), Goldman Sachs Group Inc. (0.86%), AQR Capital Management LLC (0.47%), Assenagon Asset Management S.A. (0.40%) and State Street Corp (0.31%). Insiders that own company stock include Ankit Mahadevia, Aquilo Capital Management, Llc, Cristina Larkin and Sath Shukla.
View institutional ownership trends
.

How do I buy shares of Spero Therapeutics?

Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Spero Therapeutics' stock price today?

One share of SPRO stock can currently be purchased for approximately $1.97.

How much money does Spero Therapeutics make?

Spero Therapeutics (NASDAQ:SPRO) has a market capitalization of $69.09 million and generates $18.26 million in revenue each year. The company earns $-89,760,000.00 in net income (profit) each year or ($3.48) on an earnings per share basis.

How many employees does Spero Therapeutics have?

The company employs 146 workers across the globe.

How can I contact Spero Therapeutics?

Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The official website for the company is sperotherapeutics.com. The company can be reached via phone at (857) 242-1600 or via email at ir@sperotherapeutics.com.

This page (NASDAQ:SPRO) was last updated on 9/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.